The emergence of various novel therapies over the last decade has changed the therapeutic
landscape for multiple myeloma. While the clinical outcomes have improved significantly …

Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …

Adoptive cell therapy with T cells reprogrammed to express chimeric antigen receptors (CAR-
T cells) has been highly successful in patients with hematological neoplasms. However, its …

Over the last decade, the survival outcome of patients with multiple myeloma (MM) has been
substantially improved with the emergence of novel therapeutic agents, such as proteasome …

Background The risk of second tumors after chimeric antigen receptor (CAR) T-cell therapy,
especially the risk of T-cell neoplasms related to viral vector integration, is an emerging …

PURPOSE ABBV-383, a B-cell maturation antigen× CD3 T-cell engaging bispecific
antibody, has demonstrated promising results in an ongoing first-in-human phase I study …

Adoptive transfer of chimeric antigen receptor (CAR) T lymphocytes is a powerful technology
that has revolutionized the way we conceive immunotherapy. The impressive clinical results …

Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …

Most patients with multiple myeloma experience disease relapse after treatment with a B-cell
maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients …

A fundamental limitation of T cell therapies in solid tumors is loss of inflammatory effector
functions, such as cytokine production and proliferation. Here, we target a regulatory axis of …